Cargando…
Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
Radiolabelled meta-iodobenzylguanidine (MIBG) is selectively taken up by tumours of neuroendocrine origin, where its cellular localization is believed to be cytoplasmic. The radiopharmaceutical [131I]MIBG is now widely used in the treatment of neuroblastoma, but other radioconjugates of benzylguanid...
Autores principales: | Cunningham, S. H., Mairs, R. J., Wheldon, T. E., Welsh, P. C., Vaidyanathan, G., Zalutsky, M. R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150394/ https://www.ncbi.nlm.nih.gov/pubmed/9649115 |
Ejemplares similares
-
131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992) -
New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.
por: Mairs, R. J., et al.
Publicado: (1995) -
Hybrid Molecules of Benzylguanidine and the Alkylating Group of Melphalan: Synthesis and Effects on Neuroblastoma Cells
por: Bruchelt, Gernot, et al.
Publicado: (2023) -
The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.
por: Armour, A., et al.
Publicado: (1997) -
Antitumor effects of radionuclide treatment using α-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model
por: Ohshima, Yasuhiro, et al.
Publicado: (2018)